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Background: The prescription of statins is an evidence-based treatment to reduce the risk of cardiovascular events
in patients with elevated cardiovascular risk or with a cardiovascular disorder (CVD). In spite of this, many of these
patients do not receive statins.
Methods: We evaluated the impact of a brief educational intervention in cardiovascular prevention in primary care
physicians’ prescribing behaviour regarding statins beyond their participation in a randomised controlled trial (RCT).
For this, prescribing data of all patients > 35 years who were counselled before and after the study period were
analysed (each n > 75000). Outcome measure was prescription of Hydroxymethylglutaryl-CoA Reductase Inhibitors
(statins) corresponding to patients’ overall risk for CVD. Appropriateness of prescribing was examined according to
different risk groups based on the Anatomical Therapeutic Chemical Classification System (ATC codes).
Results: There was no consistent association between group allocation and statin prescription controlling for risk
status in each risk group before and after study participation. However, we found a change to more significant
drug configurations predicting the prescription of statins in the intervention group, which can be regarded as a
small intervention effect.
Conclusion: Our results suggest that an active implementation of a brief evidence-based educational intervention
does not lead to prescription modifications in everyday practice. Physician’s prescribing behaviour is affected by an
established health care system, which is not easy to change.
Trial registration: ISRCTN71348772
Keywords: Evaluation studies, Intention to treat analysis, Cardiovascular diseases, Drug prescriptions,
Hydroxymethylglutaryl-CoA Reductase InhibitorsBackground
The prescription of statins is an evidence-based treatment
to reduce the risk of cardiovascular events in patients with
elevated cardiovascular risk or with a cardiovascular
disorder [1-4]. Nevertheless, many of those patients do not
receive statin therapy [5-8]. In a German study, Berthold* Correspondence: oliver.hirsch@staff.uni-marburg.de
†Equal contributors
1Department of General Practice/Family Medicine, Philipps University of
Marburg, Karl-von-Frisch-Strasse 4, Marburg 35043, Germany
Full list of author information is available at the end of the article
© 2013 Keller et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the oret al. found that the majority of patients with type 2 dia-
betes were not receiving statins. They were more likely to
be prescribed a statin in secondary prevention. In primary
prevention, this depended on the individual cardiovascular
risk status. The authors conclude that physicians were
generally aware of the concept of cardiovascular risk,
but they did not consistently implement evidence-based
treatments [9]. In an Italian sample less than 40% of eli-
gible patients were prescribed statins and less than half
of those receiving statins were taking wrong doses [10].
There is also a low adherence to statin therapy in patientstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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adequate information.
According to existing guidelines in the prevention
of cardiovascular disease (CVD) [12-14], we developed
arribaTM, a simple, Framingham-based [15] educational
intervention that combines risk calculation and consult-
ation based on a patient’s individual global risk for CVD to
help practitioners accommodate for the double paradigm
shift towards global cardiovascular risk and shared decision
making (SDM) [16]. SDM incorporates evidence-based
medicine and was shown to increase adherence to medical
treatment decisions [17].
We had conducted a pragmatic cluster randomized
controlled trial (RCT) and had chosen an active implemen-
tation strategy addressing continuing medical education
(CME) groups [18]. Prior to the start of the trial, arriba™
had undergone a three year phase I/II development process
[19]. We had discussed the epidemiological background of
global CVD risk calculation and the ethics of shared
decision making (SDM) with an emphasis on practical
communication strategies and materials to be applied
during consultation. Results on main outcome measures
have been recently published, including details on power
calculations, recruitment rates, and baseline characteristics
[16,20,21]. An intervention effect on prescribing could
only be found for inhibitors of platelet aggregation,
independent from individual cardiovascular risk. No
changes were observed for statin prescription rates [21].
The active implementation of a brief, evidence-based
educational intervention on the global risk of CVD did
not directly lead to risk-adjusted changes in prescription
within a period of 6 months. Therefore, the intention
was to increase the time frame regarding statin prescription
behavior and to examine whether decision support of
this kind would improve the risk-adjusted prescription
of this medication.
For assessing appropriateness of prescription, it is
important to correctly identify the respective target
population, i.e. patients with a specific condition who
should receive a specific treatment. It has been recognized
that the data source used can influence the outcome of the
quality assessment. Often either diagnostic codes or clinical
measurements are used to identify target patients [22]. The
selective recruitment of patients for RCTs might contain
such problems.
In this article we introduce an approach to evaluate
our implementation strategy on the appropriateness of
prescription beyond study participation in our RCT and
for a longer time frame than our previous study. For
this, we included prescribing data of all patients > 35 years
who had been counselled before and after the study
period. We used this data to investigate the effectiveness
of the intervention by applying an intention to treat
analysis [23] approach.Methods
Study sample
The majority of German family doctors are organised in
continuing medical education (CME) groups. Hessian
CME groups supervised by AQUA-institute, a German
quality management institute, had been offered to partici-
pate in the initial RCT (www.aqua-institut.de). We refer
to the original physician sample of our RCT [16]. We ex-
cluded CME groups if several members had already taken
part in previous meetings on arribaTM, or if they had
routinely used other cardiovascular risk calculators at
that time. As a result, we attained 14 CME groups with
162 physicians. Randomisation of the physicians to
intervention or control group was performed on CME
group level by the Centre for Clinical Trials, University
of Marburg, Germany. Participating general practi-
tioners (GPs) of the intervention arm were invited to
attend two CME sessions lasting 2 1/2 hours each. The
epidemiological background of global cardiovascular
risk calculation, as well as the ethics of shared decision
making, were discussed by emphasising practical com-
munication strategies and materials (arribaTM) to be
applied during consultation. Concurrently, GPs of the
control arm were invited to participate in seminars on
defined alternative topics not related to cardiovascular
prevention. More details about the intervention can be
found elsewhere [20].
After completing the educational sessions, partici-
pating physicians were asked to recruit a maximum
of 15 of their adult patients for the RCT. Rolling
recruitment of patients was spread evenly from May
2005 to March 2006.
For the present evaluation, all GPs who participated
in our RCT and who were registered in the Hessian
Association of Statutory Health Insurance Physicians
before study start (baseline = 1st quarter 2005) as well
as after study end (evaluation = 1st quarter 2006) and
had received continuing education were integrated in
the present investigation (Figure 1), independent of
patient recruitment in our RCT. Of those, 11 GPs
changed their registration number during the examination
period, which made data analysis impossible for those
cases (intervention group n = 5, control group n = 6).
This resulted in a total of 75 GPs in the intervention arm
(43 GPs recruited patients, 32 GPs did not) and 76 GPs in
the control arm (44 GPs recruited patients, 32 did not).
Independent of whether a GP had recruited study pa-
tients, all GPs were considered for this analysis because
of the ITT approach. Figure 1 shows characteristics of
the physician sample.
The study complies with the Declaration of Helsinki. The
research protocol was approved by the local research ethics
committee, University of Marburg, Germany. Informed
consent was obtained from all participating GPs.
Figure 1 Flow chart of participating GPs.
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We evaluated changes in prescribing behaviour using
ITT analysis since the only available data source for
evaluation was prescribing data from each participating
GP between January 2005 and December 2006; the data
was not linked to patients’ diagnoses. Data retrieval was
possible through the billing of Statutory Health Insurance-
accredited physician services with regard to the German
Social Security Statute Book (§ 295 SGB V). Prescription
was examined according to different cardiovascular risk
groups based on the Anatomical Therapeutic Chemical
Classification System (ATC codes) [24] as displayed in
Table 1. We defined four cardiovacular risk groups
(very high, high, intermediate, low) based on the prescrip-
tion of drugs with specific ATC codes. We validated this
algorithm on the basis of data of our RCT [16] with the
arribaTM risk calculation. The average cardiovascular
risk in the very high risk group was 35%, in the high
risk group it was 29%, in the intermediate risk group it
was 18%, and in the low risk group it was 7%. Outcome
measure was prescription of Hydroxymethylglutaryl-
CoA Reductase Inhibitors (statins - ATC code C10AA).
Prescription of statins was considered to be appropriate in
patients of risk groups 1 (very high risk) and 2 (high risk),
non-prescription of statins was considered to be appro-
priate in patients of risk groups 3 (intermediate risk)
and 4 (low risk).
Statistical analysis
We calculated Cochrane-Mantel-Haenszel tests in order
to examine the association between group allocation of
physicians and statin prescription controlling for risk
status of patients [23]. After stratifying on the observed
covariates, the Cochrane-Mantel-Haenszel (CMH) test is
used to measure the strength of the association betweenan exposure and a disease or response. The rows of the
resulting table correspond to the treatment group and
the columns to the dependent values. The alternative
hypothesis is that the statin prescription is conditionally
dependent of the treatment in any given strata. If this is
the case, the direction of such a significant difference
must be examined. The resulting effect is evaluated by the
effect size Cramer V. A Cramer V of .40 or higher denotes
a large effect [25,26].
Within the high risk group, we performed a prediction
configural frequency analysis (CFA) with Bonferroni-
Holm correction [27] to identify drug configurations which
predicted the description or non-description of statins
[28,29]. The non-parametric configural frequency ana-
lysis is a multivariate statistical method used to explore
associations among categorical variables. With this ap-
proach it is possible to categorize subjects and reveal
reciprocal dependencies between certain features or
characteristics. Furthermore, it is possible to examine
the influence of independent variables on dependent
variables (prediction Configural Frequency Analysis). It can
also be used to generate hypotheses (explorative CFA) and
for hypothesis testing (confirmatory CFA). Analyses were
performed using SPSS 17.0 and CFA [29].
Results
Prescribing patterns
We performed the Cochrane-Mantel-Haenszel test in
order to examine the association between group allocation
and statin prescription controlling for risk status before
the start of our RCT. The Breslow-Day test indicates the
homogeneity of the odds ratios (χ2 =3.91, p = .27). The
Cochrane-Mantel-Haenszel test signals a significant asso-
ciation between group allocation and statin prescription
after controlling for risk status (χ2 =15.05, p < .001).
Table 1 Risk group classification for cardiovascular
disease (CVD) according to the anatomical therapeutic
chemical classification system (ATC codes)
Risk group 1 = patients with very high risk
ATC Code Agents
C01DA Vasodilators used in cardiac
diseases (organic nitrates)
or
B01AC04 Clopidogrel
or
B01AC05 Ticlopidine
or
C02 and/or C03 and/or C07
and/or C08 and/or C09
Antihypertensives, diuretics,
beta blocking agents,
calcium channel blockers,
agents acting on the
renin-angiotensin system
and
A10 Antidiabetics
and
Male > 49 years or female > 54 years
Risk group 2 = patients with high risk
ATC Code Agents
C02 Antihypertensives
or
C03 Diuretics
or
C07 Beta blocking agents
or
C08 Calcium channel blocker
or
C09 Agents acting on the
renin-angiotensin system
or
A10 Antidiabetics
or
B01AA Vitamin K antagonists
or
B01AC06 Acetyl salicylic acid
and
Male > 49 years or female > 54 years
Risk group 3 = patients with intermediate risk
ATC Code Agents
C02 Antihypertensives
or
C03 Diuretics
or
C07 Beta blockers
or
Table 1 Risk group classification for cardiovascular
disease (CVD) according to the anatomical therapeutic
chemical classification system (ATC codes) (Continued)
C08 Calcium channel blocker
or
C09 Agents acting on the
renin-angiotensin system
or
A10 Antidiabetics
or
B01AA Vitamin K antagonists
or
B01AC06 Acetyl salicylic acid
Low risk group 4 = all the others
ATC Code Agents
All patients with medication
> 35 years
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common odds ratio of .894 (95%CI: .845 - .946) means
that the chance of a statin prescription is reduced by
10.6% (95%CI: 5.4% - 15.5%) in the intervention group. The
distributions in the intervention and control group are very
similar within the different risk groups. The significant
result most probably emerged because of the known
sample size dependence of χ2. The raw data before the
intervention with arribaTM are presented in Table 2.
We again performed the Cochrane-Mantel-Haenszel
test in order to examine the association between group
allocation and statin prescription controlling for risk status
after the intervention. The raw data after the intervention
with arribaTM are presented in Table 3.
The Breslow-Day test indicates the homogeneity of the
odds ratios (χ2 =2.09, p = .55). The Cochrane-Mantel-
Haenszel test reveals no significant association between
group allocation and statin prescription after controlling
for risk status (χ2 =0.76, p = .38). There was still a low
supply with statins in the very high risk intervention
group (23.3%), especially in the high risk intervention
group (11.0%). Therefore, we used a prediction configural
frequency analysis to investigate which configuration pre-
dicted the prescription or the non-prescription of statins in
the high risk group before the start of our RCT. The signifi-
cant prediction configurations are displayed in Table 4.
The two groups differ in their prediction configurations
in that the prescription of statins in the control group is
predicted by three configuration types consisting of pa-
tients with clopidogrel, with clopidogrel and nitrate, and
with antidiabetics and clopidogrel. In contrast, we mainly
found configurations that prevented the physicians from
prescribing statins in the intervention group. These are
Table 2 Cross-tabulation of risk status, group allocation, and statin prescription before the intervention with arribaTM
Risk group Statins Total Odds ratios
No Yes (95% confidence interval)
Group 1very high risk Intervention n 3745 958 4703
% 79.6% 20.4% 100.0%
Controls n 3534 878 4412 0.97
% 80.1% 19.9% 100.0% (0.88-1.08)
Group 2 high risk Intervention n 12929 1433 14362
% 90.0% 10.0% 100.0%
Controls n 11647 1125 12772 0.87
% 91.2% 8.8% 100.0% (0.80-0.95)
Group 3 intermediate risk Intervention n 2496 132 2628
% 95.0% 5.0% 100.0%
Controls n 2412 104 2516 0.82
% 95.9% 4.1% 100.0% (0.63-1.06)
Group 4 low risk Intervention n 16717 469 17186
% 97.3% 2.7% 100.0%
Controls n 16417 391 16808 0.85
% 97.7% 2.3% 100.0% (0.74-0.97)
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and with antidiabetics and nitrates.
Using a prediction configural frequency analysis, we
again investigated which configuration predicted the pre-
scription or the non-prescription of statins in the high risk
group after the intervention with arribaTM. The significant
prediction types are displayed in Table 5.Table 3 Cross-tabulation of risk status, group allocation, and
Risk group
No
Group 1 very high risk Intervention n 3905
% 76.7%
Controls n 3409
% 76.1%
Group 2 high risk Intervention n 14003
% 89.0%
Controls n 12383
% 89.4%
Group 3 intermediate risk Intervention n 2686
% 94.7%
Controls n 2459
% 95.1%
Group 4 low risk Intervention n 16823
% 96.9%
Controls n 15724
% 97.1%The distribution of significant prediction types changed
in both groups. In the intervention group there was a
change to significant configurations predicting the prescrip-
tion of statins: patients with clopidogrel, with antidiabetics
and nitrates, and with antidiabetics and clopidogrel.
In both groups the sole prescription of nitrates or of
antidiabetics predicted the non-prescription of statins.statin prescription after the intervention with arribaTM
Statins Total Odds ratios
Yes (95% confidence interval)
1183 5088
23.3% 100.0%
1069 4478 1.04
23.9% 100.0% (0.94-1.14)
1735 15738
11.0% 100.0%
1469 13852 0.96
10.6% 100.0% (0.89-1.03)
149 2835
5.3% 100.0%
127 2586 0.93
4.9% 100.0% (0.73-1.19)
538 17361
3.1% 100.0%
477 16201 0.95
2.9% 100.0% (0.84-1.08)
Table 4 Significant types in a prediction configural frequency analysis (P-CFA) before the intervention with arribaTM;
DV = dependent variable, p = level of significance
Antidiabetics Ticlopidine Clopidogrel Nitrates Statins DV p intervention group p control group
No No No Yes No p = .0002 ————
No No Yes No No p < .000001 ————
No No Yes No Yes ———— p < .000001
No No Yes Yes Yes p < .000001 p = .0005
Yes No No No No p = .000004 ————
Yes No No Yes No p = .0005 ————
Yes No Yes No Yes ———— p < .000001
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tions (statin - yes) has increased in the intervention arm,
and the number of negative prediction configurations
(statin - no) has increased in the control group. Regard-
ing the change in the intervention group, this might be
classified as an effect of the intervention. Nevertheless,
both groups are quite similar in their medication patterns
at the end of the observed time period.
Appropriateness of prescription
To examine the general appropriateness of statin pre-
scription we grouped patients with very high risk and
high risk receiving statins, and those with intermediate
and low risk not receiving statins in intervention and
control physicians. These prescriptions were labelled
as “appropriate”. We then grouped patients with very
high risk and high risk not receiving statins, and those
with intermediate and low risk receiving statins in
intervention and control physicians. These prescriptions
were labelled as “not appropriate”.
The χ2 –test signals a significant association between
group and appropriateness of prescription (χ2 (df = 1) =
17.09, p < .001) before the start of our RCT. This significant
result might be due to the sample size dependence of χ2 as
the corresponding effect size Cramer V with .015 denotes a
negligible effect. The odds ratio of 0.94 (CI 95%: 0.92-0.97)
indicates a slightly more appropriate statin prescription in
the control group.Table 5 Significant configurations in a prediction configural f
arribaTM; DV = dependent variable, p = level of significance
Antidiabetics Ticlopidine Clopidogrel Nitrates
No No No Yes
No No Yes No
No No Yes Yes
Yes No No No
Yes No No Yes
Yes No Yes No
Yes No Yes YesThe χ2 test still shows a significant association between
group and appropriateness of prescription (χ2 (df = 1) =
10.52, p = .001) after the intervention. This can again be
interpreted in the context of the sample size dependence
of χ2 as the corresponding effect size Cramer V with
.012 indicates a negligible effect. The odds ratio of 0.95
(CI 95%: 0.93-0.98) again points to a more appropriate
prescription in the control group.
Discussion
Effects on prescription
The educational intervention of our underlying RCT aimed
for a double paradigm shift towards shared decision making
and rational global cardiovascular risk management. It had
a significant impact on the communication behaviour of
participating GPs as recently published [16], but there was
hardly any effect on prescription behaviour [21]. In order to
evaluate our intervention regarding our entire physician
sample, regardless of patient recruitment for our RCT,
we analyzed prescribing data using prescription of statin
as a measurement index.
Main findings before our RCT were independent of
group allocation: the higher the risk category, the more
statins were prescribed, but much less than expected
and required by guidelines. The distribution of appropriate
risk-adapted medication (e.g., very high or high risk: statin;
intermediate or low risk: no statin) in the intervention and
control group are very similar among the different riskrequency analysis (P-CFA) after the intervention with
Statins DV p intervention group p control group
No p = .00009 p = .0014
Yes p < .000001 p < .000001
Yes ———— p = .0006
No p < .000001 p < .000001
Yes p < .000001 ————
Yes p < .000001 p < .000001
Yes ———— p = .0003
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high and very high risk patients were also independent of
group allocation. On the one hand, there might have been
a misclassification of risk due to inadequate prescribing of
nitrates without definite diagnosis of CVD. In addition,
vitamin K antagonists might have been prescribed for ven-
ous thromboembolism compatible with low CVD risk, as
well as diuretics for peripheral oedema without hyperten-
sion or heart failure. On the other hand, there might have
been a misclassification regarding our outcome parameter.
Statins prescribed by other physicians or in another quarter
of the year than we analyzed would not necessarily have
been captured by our study.
We did not explore reasons for lacking guideline adher-
ence. A high risk patient not on statin medication may have
had side effects in the past, discontinued medication on his
own, refused to take medication, or preferred to try behav-
ioural changes first. A quality problem might have occurred
because of a prescription not based on global cardiovascu-
lar risk. Consequently, it might also have been possible that
a patient with a low cholesterol level was not prescribed a
statin although his global CVD risk was high.
However, the change to more significant configurations
predicting the prescription of statin in the intervention
group can be regarded as a small intervention effect. The
physicians in both groups were not aware that the config-
urations were monitored, so that decisions in the expected
direction could not be evoked artificially. However, using
different outcome measurements, our findings here still
demonstrate a gap between recommended and current
drug use for primary prevention of CVD according to glo-
bal risk as reported by Wensing et al. [18].
Interpretation of results
A recent study has shown that measurement indices like
those applied in our study are even better when used as
a prescribing quality indicator (PQI) in comparison to
parameters based on diagnoses [22]. Although we provided
intervention GPs with information on how to treat diseases
in accordance with research evidence and guideline recom-
mendations, this was insufficient to change prescribing
behaviour. In a recently published primary care physician
survey, the authors found that providing 10 year coronary
risk information improved some hypothetical prescribing of
acetylsalicylic acid and also improved lipid management
when the CVD risk was moderately high [30]. Others iden-
tified acetylsalicylic acid underuse by some patients with
increased risk and potentially inappropriate use by some
with low risk [31-33]. Such findings align with our results
and suggest that specific guideline recommendations
should be provided along with clinical decision support and
risk assessment. Therefore, our intervention period might
have been too short to initiate such changes. Our findings
are supported by a comparison to prescribing data of atotal of 1 519 722 patients derived from the Hessian
Association of Statutory Health Insurance Physicians,
including all other GPs who had also been registered in
both investigation periods. Using the same methodo-
logical approach, we found a matchable low supply of
statins in the very high (22.6%) and high risk (11.2%)
groups. Likewise, patients in groups with intermediate
(95.5% with no statin prescription) and low cardiovas-
cular risk (97.3% with no statin prescription) were treated
similarly to the patients of our participating GPs.
It is well known that successful implementation of
innovative behaviour among professionals seems to be
more likely contingent upon various external factors
such as patients’ expectations, pressure from the wider
medical environment, or marketing by drug companies
[30,34,35]. Indeed, change requires long-running com-
prehensive approaches at different levels of the health
care system, tailored to specific settings and target groups
[36,37]. Despite this, and even with some improvement
in knowledge, patient acceptance of and adherence to
treatment recommendations may remain suboptimal
as inaccurate perceptions of vulnerability to a disease
can inhibit behavioural changes [38-40].
The remarkably low prescribing rates of statins in high
and very high risk patients might also imply methodological
aspects such as a non-registered prescription at the end of
a quarter or prescription by specialists, neither of which
could have been identified here.
Important research findings often do not translate
automatically into practice. Even a comprehensive imple-
mentation programme was not able to raise statin prescrip-
tion rates in eligible patients [5]. Thus, implementation
requires a clear and deliverable evidence-based message,
evidence that current care is suboptimal, a robust estimate
of the cost and impact of alternative methods of behavioural
change, and an understanding of the local organization
of health care [41]. More attention has to be paid to the
validation of different theories on changing professional
and organisational performance (from health promotion,
social sciences, organisational and management sciences,
marketing, and economy) to find the crucial determinants
of effective change [37].
Strengths and limitations
For reliable assessment of prescribing quality it is important
to correctly identify the patients eligible for recommended
treatment. Implementation studies usually recruit individ-
ual patients after intervention for evaluation purpose.
Therefore, they have to face the problem of selection bias
and concealment of allocation. In our study, evaluation
could be performed independently of patient recruitment
and patients’ diagnosis because of the availability of routine
prescribing data provided by the Hessian Association of
Statutory Health Insurance Physicians. However, since the
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noses, data analysis was limited. Risk group classification
equal to the RCT was impossible, although we validated
our algorithm on data of our RCT. In addition, data
analysis per protocol was not feasible. As a new approach,
prescribing behaviour was examined according to different
cardiovascular risk groups based on the Anatomical
Therapeutic Chemical Classification System. Such an
approach is admissible in order to discover important
aspects indirectly connected to the original study and also
may enhance external validity [42]. Additionally, pre-
scription data was shown to result in reliable prevalence
estimates, especially in cardiovascular diseases [43].
Our data dates back to 2005 and 2006. Nevertheless, the
clinical effectiveness and safety of statins have not changed
over the last years, neither has the approach based on abso-
lute cardiovascular risk. Lower target levels are favoured in
some countries but these are minor changes that do not
generally threaten the relevance of our work.
The knowledge and skills of the GPs regarding statin
prescription prior to the study can be assumed to be at a
similar level. This is a frequent topic in CME courses and
in central journals (http://www.aerzteblatt.de/). We reached
a balanced distribution of prior knowledge regarding statins
in both groups because of randomisation.Conclusions
Our results suggest that an active implementation of a
brief, evidence-based educational intervention does not
immediately lead to a modification in statin prescription
in everyday practice. Our findings indicate this may be the
case because physicians are embedded in an organisational
framework which prevents them from changing pre-
scription behaviour rapidly. The accordance between
GPs’ prescribing behaviour as study participants and
prescription in daily routine reveals a stable behaviour,
which is not easy to change.
Long-term and subgroup analyses are needed to investi-
gate the effects of educational interventions on prescribing
behaviour.
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